Exploring nuclear medicine
Strong shoulders supporting nuclear medicine
Medical radioisotopes are invaluable, both in detecting and fighting cancer. As a key player in the global production of these isotopes, SCK CEN actively contributes to research into and development of radioligand therapy. Which isotopes are best suited for this purpose? How can we optimise their effectiveness? Our scientists are searching for the answers.
What is radioligand therapy (RLT)?
In radioligand therapy, a carrier molecule delivers a radioactive isotope directly to the tumour and/or metastases. The cancer cells are then attacked with extreme precision, while the healthy tissue surrounding them is largely avoided. For the patient, this means fewer side effects and a better quality of life.
RReeaadd mmoorree aabboouutt ffiigghhttiinngg ccaanncceerr wwiitthh RRLLTT
Research and production
Radioligand therapy can significantly increase the life expectancy and quality of life of cancer patients. However, the supply chain is still fragile and the biological mechanisms behind it are still unknown. SCK CEN wants to unravel these mechanisms and boost the production chain.
1. Groundbreaking preclinical research
We are accelerating the development of radioligand therapy by conducting our own preclinical research. The aim of this research is to unravel the biological mechanisms behind radioligand therapy and to validate the precision and effectiveness of radiopharmaceuticals. In addition to partnerships with clinical and industrial partners, SCK CEN also runs its own cancer research programme. This programme focuses on innovative treatments for three specific types of cancer:
- Glioblastoma (brain cancer);
- Colorectal cancer;
- and ovarian cancer.
Want to know more about our preclinical research?
2. Key role in production
There are currently around 200 clinical studies in radioligand therapy underway around the world. A number of these are already in the final testing phase. We therefore expect that these therapies will be introduced into practice in the near future. The demand for medical radioisotopes will therefore increase significantly and production capacity will have to keep pace. With our BR2 research reactor and our CRF, we are getting our shoulders behind this challenge.
Want to know more about our contribution to the production of radioisotopes?
3. Open dialogue with patients, doctors and policymakers
SCK CEN is in constant open dialogue with patients, doctors and policymakers, because dialogue makes the research more relevant for society. Discover how we are active at the heart of society.
Want to know more about this dialogue?
Recent RLT news of us
Increase the life-saving potential of your molecules
Our aim is to accelerate the development of new radiopharmaceuticals for cancer treatment. Our in-house expert teams conduct research to support this goal, and we also make our extensive knowledge and facilities available to external partners. Through our research and innovative infrastructure, we help pave the way for future commercial production.